Produkt
KI-AGENTEN
KI-ANWENDUNGEN
SONSTIGES
Lösungen
BRANCHEN
USE CASES
Preisgestaltung
Ressourcen
ENTDECKEN
ENGAGIEREN
SUPPORT & DIENSTLEISTUNGEN
Über
PatSnap Eureka-Plattform
Vertreter für geistiges Eigentum
Agenturen für Ingenieurwesen
Vertreter für den Bereich Life Sciences
Vertreter für Werkstoffe
PatSnap Eureka Desktop
NEWAnalytik
IP-IntelligenzSynapse
Biopharma-IntelligenceBiografie
Suche und Analyse von BiosequenzenChemikalie
Suche und Analyse chemischer StrukturenOffene Plattform
NEWProfessionelle Dienstleistungen
Kundenberichte
Newsroom
Blog
Globaler Innovationsbericht
Glossar
Webinare & Schulungen
Grenze
Benutzergemeinschaft
R&D Benchmark Calculator
Vertrauen und Sicherheit
PatentBench
NEWLLM
Hilfezentrum
Karriere
Zugriff auf über 2.000.000.000 strukturierte Datenpunkte aus den Bereichen Patente, Wissenschaft, Rechtsstreitigkeiten und Technologie
75 % schneller innovativ sein bei 25 % geringeren Kosten
Cloud oder lokal für maximale Privatsphäre und Kontrolle
Vertrauen von mehr als 18.000 Innovatoren weltweit
Um die Funktion zu nutzen, klicken Sie auf den Bestätigungsbutton in der E-Mail, die wir an [email protected] gesendet haben .
Dies trägt zur Sicherheit Ihres Kontos bei.
Sie sollten es in Kürze erhalten. Vergessen Sie nicht, Ihren Spam-Ordner zu überprüfen.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Sorgfältig zusammengestellte Reihe mit wertvollen Einblicken für Innovationsfachleute
Artikel | Bericht How sacituzumab govitecan and next-gen TROP2 ADCs are reshaping endometrial and urothelial cancer treatment — and what resistance mechanisms mean for the pipeline.
Artikel | Bericht How federated learning enables AI model training across distributed manufacturing sites without sharing raw data — architecture, privacy, and industrial deployment.
Artikel | Bericht Ifinatamab deruxtecan's DeLLphi-304 Phase III trial is redefining first-line small cell lung cancer treatment. Explore the science, patent landscape, and clinical implications.
Artikel | Bericht No verified patent or literature data was found for deterministic latency in industrial Ethernet for real-time robot control. Learn what this means for your research.
Artikel | Bericht Ulotaront, ralmitaront, and the TAAR1 agonist pipeline are reshaping schizophrenia and depression drug discovery. See the competitive landscape.
Artikel | Bericht Explore the key technical tradeoffs between hydrogen combustion and fuel cell powertrains for aviation — efficiency, weight, emissions, and integration challenges.
Artikel | Bericht Roche's trontinemab uses a transferrin receptor brain-shuttle to deliver amyloid-beta antibody at higher brain concentrations with a differentiated ARIA profile. Full Phase II analysis.
Artikel | Bericht How do model-based and data-driven fault detection methods compare for industrial rotating machinery? A technical guide for R&D and IP professionals.
Artikel | Bericht Oveporexton is the first orexin receptor agonist targeting narcolepsy type 1. Explore its FDA approval trajectory, mechanism, and competitive market dynamics.
Artikel | Bericht Key engineering challenges of building reliable humanoid robots for industrial deployment at scale — from actuator reliability to locomotion control and dexterity.
Artikel | Bericht Explore the key differences between physics-based and data-driven modeling for industrial process optimization, including hybrid approaches and when to use each.
Artikel | Bericht Tirzepatide's SURPASS-CVOT trial examines GLP-1/GIP dual agonist cardiovascular and renal outcomes in type 2 diabetes. Explore the science, IP landscape, and clinical significance.
Artikel | Bericht How do open-source and proprietary LLMs differ for enterprise R&D? Compare customisation, cost, compliance, and performance to make smarter AI deployment decisions.
Artikel | Bericht Sparsentan targets both ETA and AT1 receptors for FSGS and IgAN treatment. Explore the dual receptor antagonism mechanism, IP landscape, and clinical signals.
Artikel | Bericht IMerge Phase 3 trial: imetelstat achieved 39.8% 8-week transfusion independence vs 15% placebo in lower-risk MDS. Full pipeline analysis and biomarker data.